Logo image of IMAC

IMAC HOLDINGS INC (IMAC) Stock Fundamental Analysis

NASDAQ:IMAC - Nasdaq - US44967K1043 - Common Stock - Currency: USD

1.01  +0.02 (+2%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IMAC. IMAC was compared to 108 industry peers in the Health Care Providers & Services industry. IMAC has a bad profitability rating. Also its financial health evaluation is rather negative. IMAC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IMAC had negative earnings in the past year.
IMAC Yearly Net Income VS EBIT VS OCF VS FCFIMAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -2M -4M -6M -8M -10M

1.2 Ratios

Industry RankSector Rank
ROA -48.41%
ROE N/A
ROIC -45.82%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMAC Yearly ROA, ROE, ROICIMAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 50 -50 100

1.3 Margins

Industry RankSector Rank
OM -72.27%
PM (TTM) -76.98%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMAC Yearly Profit, Operating, Gross MarginsIMAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -500 -1K -1.5K

More info and screens

2

2. Health

2.1 Basic Checks

IMAC has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for IMAC has been increased compared to 1 year ago.
The debt/assets ratio for IMAC has been reduced compared to a year ago.
IMAC Yearly Shares OutstandingIMAC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M
IMAC Yearly Total Debt VS Total AssetsIMAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -0.90, we must say that IMAC is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 0.01 indicates that IMAC is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -0.9
ROIC/WACC-5.63
WACC8.14%
IMAC Yearly LT Debt VS Equity VS FCFIMAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 5M -5M 10M 15M

2.3 Liquidity

IMAC has a Current Ratio of 1.27. This is a normal value and indicates that IMAC is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.27 indicates that IMAC should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
IMAC Yearly Current Assets VS Current LiabilitesIMAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M

More info and screens

6

3. Growth

3.1 Past

IMAC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.64%, which is quite good.
Looking at the last year, IMAC shows a very strong growth in Revenue. The Revenue has grown by 21.05%.
The Revenue has been growing by 272.72% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)13.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)21.05%
Revenue growth 3Y29.01%
Revenue growth 5Y272.72%
Sales Q2Q%27.29%

3.2 Future

Based on estimates for the next years, IMAC will show a small growth in Earnings Per Share. The EPS will grow by 2.32% on average per year.
IMAC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.61% yearly.
EPS Next Y2.98%
EPS Next 2Y7.43%
EPS Next 3Y4.29%
EPS Next 5Y2.32%
Revenue Next Year21.45%
Revenue Next 2Y23.21%
Revenue Next 3Y22.4%
Revenue Next 5Y22.61%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IMAC Yearly Revenue VS EstimatesIMAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
IMAC Yearly EPS VS EstimatesIMAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMAC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMAC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMAC Price Earnings VS Forward Price EarningsIMAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -2.44
IMAC Per share dataIMAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.43%
EPS Next 3Y4.29%

More info and screens

0

5. Dividend

5.1 Amount

IMAC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMAC HOLDINGS INC

NASDAQ:IMAC (8/5/2022, 8:25:24 PM)

1.01

+0.02 (+2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-12 2022-05-12/amc
Earnings (Next)08-23 2022-08-23/bmo
Inst Owners11.86%
Inst Owner Change-2.36%
Ins Owners8.88%
Ins Owner Change0%
Market Cap26.75M
Analysts80
Price Target3.59 (255.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.76
P/FCF N/A
P/OCF N/A
P/B 1.79
P/tB N/A
EV/EBITDA -2.44
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.57
BVpS0.57
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.41%
ROE N/A
ROCE N/A
ROIC -45.82%
ROICexc N/A
ROICexgc -99.32%
OM -72.27%
PM (TTM) -76.98%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z -0.9
F-Score4
WACC8.14%
ROIC/WACC-5.63
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y2.98%
EPS Next 2Y7.43%
EPS Next 3Y4.29%
EPS Next 5Y2.32%
Revenue 1Y (TTM)21.05%
Revenue growth 3Y29.01%
Revenue growth 5Y272.72%
Sales Q2Q%27.29%
Revenue Next Year21.45%
Revenue Next 2Y23.21%
Revenue Next 3Y22.4%
Revenue Next 5Y22.61%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A